Cleo Diagnostics Expands IP Portfolio with Provisional Patents for Ovarian Cancer Screening Test
Get your Free Report on Top 5 ASX stocks for 2025
Ovarian cancer diagnostics developer Cleo Diagnostics Limited (ASX: COV) announced on 30 September 2026 that it has lodged two new provisional patent applications to safeguard intellectual property generated from its screening test development program.
The dual filings establish an initial priority position centered on candidate biomarker combinations and their specific utility in detecting ovarian cancer at early stages.
Cleo has confirmed plans to follow up with an international Patent Cooperation Treaty (PCT) application within the standard 12 month priority window to secure coverage across major commercial jurisdictions ahead of its anticipated proof of concept data readouts in early Q4 CY2026.
The company also highlighted that securing proprietary protection is critical to addressing a major unmet clinical need as roughly 51% of ovarian cancer patients succumb within five years largely due to late diagnosis and the absence of routine screening protocols.
Expanding the biomarker estate allows the group to accelerate commercial readiness and broaden clinical access for high risk and asymptomatic populations.
The screening program leverages the CXCL10 biomarker platform developed under Cleoβs advanced pre-surgical triage test which is currently progressing through pivotal validation toward an FDA regulatory submission.
The new patents deepen the firmβs defensive barrier as it systematically transitions the core technology from surgical triage into global screening applications.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
Stakk Secures FBI Deployment for Signature Verific..
Rubicon Water Secures $12M Irrigation Modernisatio..
Memphasys Targets Fast-Track FDA Pathway for Felix..
Mesoblast Secures FDA Clearance for New Ryoncil Co..
BCAL Diagnostics (ASX:BDX) Launches Avantect Multi..